Systemic Inflammation Relief for COPD
Inflammation plays a key role in Chronic Obstructive Pulmonary Disease (COPD). More than 16 million Americans suffer from COPD, which is also the fourth leading cause of death in the United States.
COPD begins as a local inflammation in the lungs. However, COPD affects a multitude of body systems remote from the lung. These include weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others. Low-grade, chronic systemic inflammation is one of the key mechanisms underlying these systemic effects. These extra-pulmonary symptoms of COPD are common and critical for the patient wellbeing and prognosis.
Inflammation Damages the Airways and Lungs
COPD, chronic bronchitis and emphysema, are all characterized by chronic and progressive airflow limitation in the lungs.
COPD is caused by an abnormal inflammatory response of the lungs to cigarette smoking, air pollution, working for many years in a dusty environment and frequent bacterial infections of the upper respiratory system.
When the lungs are irritated by noxious particles or gases, they swell and produce a large amount of mucus. If inflammation persists for a long period, the protease enzymes released by inflammatory cells can damage the walls of the airways and cause airway obstruction.
COPD Is A Systemic Inflammatory Disease
COPD Involves Systemic Inflammation
According to several studies, COPD involves not only inflammatory response in the airway and the lungs, but also systemic inflammation. There is evidence that stable COPD is associated with low-level systemic inflammation as demonstrated by an increase in C reactive protein (CRP, an inflammatory marker) and cytokines (small proteins that affect communications, growth and death of cells). The levels of inflammatory markers are inversely related to airflow limitation.
During acute exacerbations of COPD (worsening of COPD symptoms), the inflammatory response is further increased. Systemic inflammation induces oxidative stress, damages cellular proteins, membrane and DNA, and results in widespread effects.
Systemic Inflammation Increases Cardiovascular Injury in COPD
Cigarette smoke increases the risk of cardiovascular disease (CVD). Smokers with COPD have a higher risk of CVD compared with those without COPD. This risk further increases with increased severity of COPD and is highest among people hospitalized for COPD.
In patients diagnosed with cardiovascular disease, COPD is associated with increased cardiovascular events, i.e., heart attack, irregular heartbeat, and heart failure. Emerging evidence suggests that increased oxidative stress that occurs during exacerbations of COPD, together with the enhanced systemic inflammatory response, have direct harmful effects on cardiac muscles and arteries. It is proven that increased inflammatory response destabilizes atherosclerotic plaques, promotes clot formation and triggers heart attack.
Systemic Inflammation Leads to Skeletal Muscle Dysfunction in COPD
Skeletal muscle dysfunction in COPD is apparent which is characterized by a reduction in muscle strength and loss of muscle mass. Loss of muscle mass is a complex process that involves changes in protein metabolism and muscle cell turnover. Impaired protein metabolism may result in muscle atrophy when protein degradation exceeds protein synthesis.
There is adequate proof that increased inflammatory response contributes to muscle atrophy by increasing protein degradation and cell death, and reducing protein synthesis and cell regeneration. Other factors include poor nutrition, inactivity, heart failure, and reduced antioxidant defenses.
Systemic Inflammation contributes to Osteoporosis in COPD
As many as 35 to 60% of patients with COPD also suffer from osteoporosis. As the severity of COPD progresses, the proportion of patients with osteoporosis increases. Many patients remain undiagnosed until their first fracture. With progressive loss of bone mass, the patient is at high risk for vertebral or hip fractures. Fractures cause significant morbidity such as pain, worsened respiratory function, decreased mobility, and even mortality.
There are numerous risk factors that contribute to osteoporosis seen in COPD patients. These risk factors include smoking, vitamin D deficiency, low body mass, defects of the reproductive system, sedentary lifestyle, and use of glucocorticoids. Now we know that systemic inflammation may be the most important risk factor contributing to osteoporosis in COPD.
Systemic Inflammation sets up depression and anxiety in COPD
Depression and anxiety are common in COPD, which occur in 20-50% of COPD patients. They can adversely affect the course of COPD. Anxiety, for example, is associated with more severe dyspnea (difficulty in breathing) and greater disability. It also is a significant predictor of the frequency of hospitalizations for acute exacerbations of COPD.
Science has revealed that systemic inflammation plays an important role in depression. Inflammatory toxins can get into the brain and suppress neurotransmitters. In COPD, difficulty breathing can keep you from doing activities that you enjoy. And it is also very difficult to deal with the disease that is progressive and incurable. Talk to your doctor if you feel sad or helpless or think that you may be experiencing depression.
FlameEz-Lung Offers Relief of Systemic Inflammation - A Whole Body Approach To COPD
There is no cure for COPD. Current treatments focus on relieving the symptoms through:
- Bronchodilators that relax the bronchial muscles so the airways are widened, making it easier to breathe
- Antibiotics that reduce bacterial infection
- Steroids that help relax the airways and make breathing easier
These drugs are usually not prescribed for long-term use because of their harmful side effects. Furthermore, they do not control inflammatory response and have no positive impact on other organ dysfunctions.
FlameEz-Lung is a patent pending all natural remedy that is scientifically formulated to deliver high performance and achieve optimal inflammation relief. The formula does not contain cough suppressant or antihistamines making it suitable for long term use. It can be combined with cough suppressant.
FlameEz-Lung will remove inflammatory toxins and:
- Clear airway obstruction and ease cough and help breathe easier*
- Remove lung destroying cells and reduce lung and airway tissue damage*
- Promote lung and airway tissue healing and repair*
- Relieve systemic inflammation, a major aging factor and a primary contributor to many chronic diseases*
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Because systemic inflammation is a common trigger in COPD and multiple organ dysfunctions, control of inflammation offers more than symptom relief. It may be vital in slowing disease progression!
Click Here For scientific literature and references.
Sign up for our monthly Newsletter for news and tips on fighting inflammation and staying healthy.
Important: What you read here is not a substitute for a medical diagnosis or treatment. Please contact your physician to diagnose, treat, cure, or prevent any disease.
Order Here (60-day Supply) 20% OFF
